Nav: Home

Cocktail of bacteria-killing viruses prevents cholera infection in animal models

February 01, 2017

BOSTON (Feb. 1, 2017)--Oral administration of a cocktail of three viruses, all of which specifically kill cholera bacteria, prevents infection and cholera-like symptoms in animal model experiments, report scientists from Tufts University School of Medicine (TUSM) and the Sackler School of Graduate Biomedical Sciences at Tufts in Nature Communications on Feb. 1. The findings are the first to demonstrate the potential efficacy of bacteria-killing viruses--known as bacteriophages, or phages--as an orally administered preventive therapy against an acute gastrointestinal bacterial disease.

"While phage therapy has existed for decades, our study is proof-of-principle that it can be used to protect against infection and intervene in the transmission of disease," said senior study author Andrew Camilli, Ph.D., Howard Hughes Medical Institute Investigator and professor of molecular biology and microbiology at TUSM. "We are hopeful that phages can someday be a tool in the public health arsenal that helps decrease the global burden of cholera, which affects up to four million people around the world each year."

In previous work, Camilli and colleagues searched for phages that are specific for Vibrio cholerae, the bacterium that causes cholera--a potentially lethal infectious disease marked by severe diarrhea and dehydration. While phages that kill V. cholerae are abundant in nature, the team identified three strains that uniquely retained the ability to kill V. cholerae within the small intestine, the site of infection in humans. These phages function by targeting bacterial surface receptors normally involved in infectiousness, making them ideal therapeutic candidates--to develop resistance, cholera bacteria must acquire mutations in these receptors, which cause the bacteria to become less infectious.

Prevent and protect

In the current study, a team comprised of Camilli, Minmin Yen, Ph.D., recent graduate of the Molecular Microbiology Program at the Sackler School, and postdoctoral fellow Lynne Cairns, Ph.D., carried out a series of experiments in small animal models of cholera to test the efficacy of these phages as a preventative treatment. Animals were given an oral dose of a cocktail containing all three phages, at time points ranging from three to 24 hours before infection with a standardized amount of V. cholerae bacteria.

A preventative dose of the phage cocktail eliminated V. cholerae in the small intestines of over half of treated animals when given three hours before infection. In remaining animals, and for those treated up to 24 hours before infection, bacteria numbers were reduced 500-fold or more on average, compared to untreated controls. Overall, treatment was most effective in reducing bacterial load when given between three and 12 hours before infection.

The team found no evidence of cholera-like diarrhea and no significant weight loss in treated animals.

To study bacterial resistance, one of the historical obstacles to the use of phages as a therapy, the researchers isolated V. cholerae that survived treatment and conducted whole-genome and molecular analyses. While some bacteria acquired resistance against one or two of the phages, no bacteria were resistant to all three phages in the cocktail. As expected based on previous work, surviving bacteria that developed phage resistance had mutations in key protein receptors that rendered the bacteria avirulent and unable to cause infection.

"It took almost a decade of work, from our lab and collaborators around the world, to identify these phages, understand their life cycle, reveal the underlying biology and mechanisms by which they attack cholera and show how resistance develops," said lead study author Minmin Yen, who conducted this research as part of her graduate thesis and is now a postdoctoral fellow in the Camilli lab. "By building on that work, we are now able to demonstrate that these phages can be effective at protecting against cholera and that the bacteria do not develop resistance to the phage cocktail."

Filling a treatment gap

Discovered roughly a century ago, bacteriophages have remained relatively unexplored in Western medicine as a therapy due to the prevalence of antibiotics. However, the dramatic rise of antibiotic-resistant bacteria has led to renewed interest in phage therapy, which can target specific strains of harmful bacteria while leaving host cells and beneficial bacteria unaffected.

Carried by contaminated water, cholera spreads quickly through communities during outbreaks. A primary path of transmission is from infected individuals to other household members, a process that typically occurs within one to two days. The research team envisions the phage cocktail as a rapid-acting preventative oral medication that can be repeatedly taken during this critical window. Reducing household transmission when an outbreak begins would help slow the spread of cholera and lessen the impact of the disease on communities.

With animal model experiments established, Camilli's team and collaborators are now exploring human clinical trials. Phage therapy has a well-established safety profile in humans, based on decades of use in eastern European countries such as Georgia. In addition, phages are the most abundant organism on Earth, and humans are continuously exposed to them with no harm. The team is also investigating the production of phages at scale, and believes that it can be done economically and priced appropriately for use in the developing world. They recently formed a company--PhagePro, which received seed funding as a winner in the Tufts 100K New Ventures Competition--to further test and develop their phage cocktail. Tufts University has filed a related patent application.

If successful, their efforts could lead to an important tool for public health professionals. A cholera vaccine exists and is recommended by the World Health Organization, but needs to be given at least two weeks in advance to be effective. Rehydration therapy is the standard treatment for cholera, but clean water is typically hard to come by during an outbreak. Antibiotics are effective at eliminating cholera bacteria, but they contribute to the spread of antibiotic-resistant strains and can harm beneficial bacteria such as those in the large intestine.

"A preventative phage treatment is unlikely to eradicate cholera, but we think that it could fill an important gap in treatment, which is immediate protection against transmission in households," said Camilli, who is also faculty in the Molecular Microbiology Program at the Sackler School. "Additional work needs to be done, particularly a deeper understanding of phage biology while inside the gastrointestinal system, but if we are able to confirm its safety profile and efficacy in humans, it has the potential to be the best option for many communities affected by cholera."
This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award AI055058) and the Howard Hughes Medical Institute.

Yen et al. "A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models." Nature Communications (2017). DOI: 10.1038/ncomms14187.

About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences

Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences are international leaders in medical and population health education and advanced research. Tufts University School of Medicine emphasizes rigorous fundamentals in a dynamic learning environment to educate physicians, scientists, and public health professionals to become leaders in their fields. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, the biomedical sciences, and public health, as well as for research at the cellular, molecular, and population health level. The School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its effect on the advancement of medical and prevention science.

Tufts University, Health Sciences Campus

Related Bacteria Articles:

Bacteria might help other bacteria to tolerate antibiotics better
A new paper by the Dynamical Systems Biology lab at UPF shows that the response by bacteria to antibiotics may depend on other species of bacteria they live with, in such a way that some bacteria may make others more tolerant to antibiotics.
Two-faced bacteria
The gut microbiome, which is a collection of numerous beneficial bacteria species, is key to our overall well-being and good health.
Microcensus in bacteria
Bacillus subtilis can determine proportions of different groups within a mixed population.
Right beneath the skin we all have the same bacteria
In the dermis skin layer, the same bacteria are found across age and gender.
Bacteria must be 'stressed out' to divide
Bacterial cell division is controlled by both enzymatic activity and mechanical forces, which work together to control its timing and location, a new study from EPFL finds.
How bees live with bacteria
More than 90 percent of all bee species are not organized in colonies, but fight their way through life alone.
The bacteria building your baby
Australian researchers have laid to rest a longstanding controversy: is the womb sterile?
Hopping bacteria
Scientists have long known that key models of bacterial movement in real-world conditions are flawed.
Bacteria uses viral weapon against other bacteria
Bacterial cells use both a virus -- traditionally thought to be an enemy -- and a prehistoric viral protein to kill other bacteria that competes with it for food according to an international team of researchers who believe this has potential implications for future infectious disease treatment.
Drug diversity in bacteria
Bacteria produce a cocktail of various bioactive natural products in order to survive in hostile environments with competing (micro)organisms.
More Bacteria News and Bacteria Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at